Research Analysts Issue Forecasts for PLX FY2027 Earnings

Protalix BioTherapeutics, Inc. (NYSE:PLX) – Analysts at HC Wainwright reduced their FY2027 earnings estimates for Protalix BioTherapeutics in a research note issued to investors on Wednesday, September 9th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings of $0.11 per share for the year, down from their previous estimate of $0.12. HC Wainwright currently has a “Buy” rating and a $12.00 target price on the stock. The consensus estimate for Protalix BioTherapeutics’ current full-year earnings is $0.01 per share. HC Wainwright also issued estimates for Protalix BioTherapeutics’ Q4 2027 earnings at $0.06 EPS.

Protalix BioTherapeutics Price Performance

PLX stock opened at $2.67 on Thursday. The business has a 50-day moving average price of $2.42 and a 200 day moving average price of $2.33. The company has a market capitalization of $215.13 million, a P/E ratio of -20.54 and a beta of 0.02. Protalix BioTherapeutics has a 1-year low of $1.60 and a 1-year high of $3.19.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. BlackRock Inc. purchased a new stake in shares of Protalix BioTherapeutics during the 2nd quarter worth $9,429,000. Geode Capital Management LLC purchased a new position in Protalix BioTherapeutics in the second quarter valued at about $1,223,000. Jane Street Group LLC raised its holdings in Protalix BioTherapeutics by 894.3% in the fourth quarter. Jane Street Group LLC now owns 289,917 shares of the company’s stock worth $522,000 after purchasing an additional 326,417 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in Protalix BioTherapeutics by 932.7% in the first quarter. Dimensional Fund Advisors LP now owns 296,843 shares of the company’s stock worth $644,000 after purchasing an additional 268,099 shares in the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Protalix BioTherapeutics by 482.3% during the first quarter. Goldman Sachs Group Inc. now owns 289,461 shares of the company’s stock valued at $741,000 after buying an additional 239,751 shares during the last quarter. 16.53% of the stock is currently owned by hedge funds and other institutional investors.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics (NYSE:PLX) is a clinical?stage biopharmaceutical company focused on the development and manufacturing of recombinant therapeutic proteins through its proprietary ProCellEx® plant cell–based expression system. Headquartered in Carmiel, Israel, with operations in the United States, the company leverages its technology platform to produce complex biologics in a cost?effective and scalable manner. Protalix’s core expertise lies in engineering plant cells to generate high?quality therapeutic proteins for rare and specialty diseases.

The company’s first approved commercial product, ELELYSO® (taliglucerase alfa), received regulatory approval from the U.S.